Barry Simon Sells 165,000 Shares of ImmunityBio (NASDAQ:IBRX) Stock

ImmunityBio, Inc. (NASDAQ:IBRX) Director Barry Simon sold 165,000 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the completion of the sale, the director owned 2,925,821 shares in the company, valued at $29,989,665.25. This represents a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

ImmunityBio Price Performance

IBRX opened at $9.54 on Thursday. The firm has a market capitalization of $9.81 billion, a P/E ratio of -25.11 and a beta of 0.16. ImmunityBio, Inc. has a one year low of $1.83 and a one year high of $12.43. The company has a fifty day moving average price of $4.97 and a 200-day moving average price of $3.28.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $38.29 million during the quarter. On average, analysts expect that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on IBRX shares. Jefferies Financial Group upped their price objective on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. HC Wainwright raised their price objective on shares of ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. Piper Sandler increased their target price on ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Finally, BTIG Research lifted their price target on ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.60.

Hedge Funds Weigh In On ImmunityBio

A number of large investors have recently added to or reduced their stakes in the business. Slow Capital Inc. bought a new stake in ImmunityBio in the third quarter worth $25,000. Truist Financial Corp purchased a new position in shares of ImmunityBio in the third quarter worth about $27,000. Swiss Life Asset Management Ltd purchased a new position in shares of ImmunityBio in the third quarter worth about $27,000. WealthPlan Investment Management LLC bought a new stake in shares of ImmunityBio in the 4th quarter valued at about $27,000. Finally, Diversify Advisory Services LLC purchased a new stake in ImmunityBio during the 2nd quarter valued at about $27,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ANKTIVA commercial adoption drove a multi‑hundred percent revenue increase, the headline catalyst for the recent rally — investors are treating this as evidence sales are scaling. Read More.
• Positive Sentiment: Multiple outlets report ~600–700% YoY revenue growth attributed to ANKTIVA uptake, reinforcing momentum and driving buying interest. Read More.
• Positive Sentiment: Regulatory/approval expansions and new commercial partnerships for ANKTIVA broaden the company’s global market opportunity—supports multi‑region revenue upside. Read More.
• Positive Sentiment: Q4 results beat consensus (smaller EPS loss and stronger revenue), which validated the commercial story in the near term and triggered bullish analyst notes. Read More.
• Neutral Sentiment: Analysis pieces highlight a disconnect between clinical progress, long‑term fundamentals and extreme short‑term price moves — useful context for risk/reward but not an immediate catalyst. Read More.
• Neutral Sentiment: Analysts (including HC Wainwright) kept bullish long‑term targets while adjusting near‑term EPS — supports a multi‑year upside thesis but adds short‑term uncertainty. Read More.
• Negative Sentiment: Insider selling: Director Barry J. Simon and others sold significant blocks in recent days, which can signal profit‑taking and weigh on sentiment. Read More.
• Negative Sentiment: Company remains unprofitable and consensus still forecasts a net loss for the current year — valuation and execution risks remain if commercial growth stalls. Read More.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.